Windlas Biotech Appoints Dr. Tarashree Singhal as Independent Woman Director
Windlas Biotech announced two board-level changes on May 5, 2026: the appointment of Dr. Tarashree Singhal (DIN: 11697518) as Additional Director and Independent Woman Director for five consecutive years, subject to shareholder approval, and the cessation of Mr. Srinivasan Venkataraman (DIN: 01132306) upon completion of his five-year term as Independent Director. The changes were disclosed under Regulation 30 of SEBI (LODR) Regulations, 2015.
*this image is generated using AI for illustrative purposes only.
Windlas Biotech Limited announced a change in its board of directors on May 5, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board of Directors, through a resolution dated May 5, 2026, approved the appointment of a new Independent Woman Director and acknowledged the cessation of an existing Independent Director upon completion of his term. The intimation was filed with both BSE Limited and the National Stock Exchange of India Limited by Company Secretary and Compliance Officer Ananta Narayan Panda.
Board-Level Changes at a Glance
The two key changes to the board composition are summarised below:
| Parameter: | Details |
|---|---|
| Appointment — Name: | Dr. Tarashree Singhal (DIN: 11697518) |
| Designation: | Additional Director / Independent Woman Director |
| Effective Date of Appointment: | May 5, 2026 |
| Tenure: | 5 consecutive years |
| Subject To: | Approval of Shareholders |
| Recommended By: | Nomination & Remuneration Committee |
| Cessation — Name: | Mr. Srinivasan Venkataraman (DIN: 01132306) |
| Reason for Cessation: | Completion of five-year term as Independent Director |
| Effective Date of Cessation: | May 6, 2026 (close of business hours on May 5, 2026) |
Appointment of Dr. Tarashree Singhal
Dr. Tarashree Singhal has been appointed as an Additional Director and Independent Woman Director of Windlas Biotech with effect from May 5, 2026, based on the recommendation of the Nomination and Remuneration Committee. The appointment is for a period of five consecutive years and remains subject to the approval of shareholders. Dr. Tarashree Singhal holds an MBBS Degree from Mysore University and a PG Diploma in Ultrasonography from Annamalai University, and brings over 26 years of experience as a medical practitioner. She has been confirmed as not debarred from holding the office of director by virtue of any SEBI order or any other such authority. Her relationship with other directors has been disclosed as independent.
Cessation of Mr. Srinivasan Venkataraman
Mr. Srinivasan Venkataraman (DIN: 01132306) has completed his five-year term as an Independent Director of the company. He ceases to be a director with effect from the close of business hours on May 5, 2026, with the effective date of cessation being May 6, 2026. Consequent to his cessation as a director, Mr. Venkataraman also ceases to be a member and chairman of the committees on which he served.
Regulatory Compliance
The disclosures pertaining to this change in directorate have been made in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular Ref: HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026. The detailed profile of Dr. Tarashree Singhal was submitted as Annexure I along with the regulatory filing.
How might Dr. Tarashree Singhal's medical background influence Windlas Biotech's strategic direction in healthcare or pharmaceutical product development?
Which board committees previously chaired by Mr. Srinivasan Venkataraman will need new leadership, and how could this transition affect governance continuity?
Will shareholders raise any concerns during the approval process for Dr. Singhal's appointment, and what timeline is expected for the shareholder vote?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
